Donald J Trump (R) Buys Insulet (PODD) Stock
Donald Trump disclosed a purchase of Insulet shares valued between $50,001 and $100,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Donald J Trump (R) bought between $50,001 and $100,000 of Insulet Corporation ($PODD) stock on May 22, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed July 1, 2026.
Since the trade, $PODD is down 6.4% after 1 week, down 10.3% after 1 month and down 8.9% to date (from the $154.87 close on May 22, 2026).
Financial Disclosure Report
United States Congress • Office of Public Records • Washington, DC
Filer Information
- Name:
- Donald J Trump (R)
- Status:
- Member
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Insulet Corporation ($PODD) | Buy | May 22, 2026 | $50,001 - $100,000 |
Summary of the filed report, not the original document.
PODD
Insulet Corporation
Key Points
- Donald Trump purchased shares of Insulet Corporation, valued between $50,001 and $100,000, as reported on July 1, 2026.
- Insulet Corporation, a medical devices company, traded at $152.25 on Wednesday and has a market cap of about $10.5 billion.
- Analysts have varied opinions on Insulet, with price targets ranging from $165 to $360, and a consensus rating of strong buy.
Get $PODD trade alerts by text
We text you when insiders, Congress or big funds trade $PODD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Insulet Corporation alert may contain errors. Disclosures
On July 1, 2026, Donald Trump, a prominent figure in the Republican Party, disclosed his purchase of Insulet Corporation shares, valued between $50,001 and $100,000. This transaction was reported under the STOCK Act, which mandates that members of Congress and certain executive officials disclose their stock trades.
Donald J Trump vs. the S&P 500
Hypothetical returns from Donald J Trump's disclosed trades, not real profit or advice. How we model this.
Insulet Corporation Stock Up 9.7%
Shares of NasdaqGS:PODD traded near $152.25 on Wednesday. Insulet Corporation, a company in the medical devices sector, has a market capitalization of approximately $10.5 billion. The stock's P/E ratio stands at 35.6, with a forward P/E of 18.8, indicating investor expectations of future earnings growth. Insulet's 52-week range is between $138.79 and $354.88, reflecting significant volatility. The company has a 50-day moving average of $159.13 and a 200-day moving average of $250.53, with a beta of 1.125, suggesting moderate market risk.
Recent Earnings
Insulet Corporation reported revenue of $2.9 billion, with a growth rate of 33.9%. The company achieved a net margin of 10.4% and return on equity of 23%. Earnings per share were $4.28. Investors can look forward to the next earnings report on August 6, 2026.
Insider Buying and Selling at Insulet Corporation
Several Insulet insiders were active in the market recently. On June 3, 2026, Timothy Stonesifer acquired 2,790 shares at an average price of $143.51, while Elizabeth Weatherman purchased 3,450 shares at $144.20. Additionally, on May 20, 2026, Luciana Borio, Timothy Scannell, and Robert Luther Huffines each bought 1,660 shares, although the transaction price was not specified.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank initiated coverage on Insulet with a 'buy' rating and a $190 price target. Truist Securities maintained its 'buy' rating with a $219 target on June 12, 2026. Citigroup, on May 28, 2026, held a 'hold' rating with a target of $165. Overall, the consensus among 24 analysts is a strong buy, with a mean price target of $240.25.
About Insulet Corporation
Insulet Corporation, headquartered in Acton, Massachusetts, is a healthcare company specializing in medical devices. It develops and sells insulin delivery systems for people with insulin-dependent diabetes. The company's flagship products include the Omnipod platform, which features automated insulin delivery systems and insulin management systems. Under the leadership of CEO Ashley A. McEvoy, Insulet employs around 5,400 people.
Bottom Line
Donald Trump's recent purchase of Insulet Corporation shares highlights the interest in this medical devices company. While the disclosed trade is backward-looking, it provides a glimpse into the investment activities of prominent figures. Investors will continue to monitor Insulet's performance, particularly given its strong earnings growth and analyst optimism.
Related Filing Alerts
Source: Donald J Trump's STOCK Act disclosure on $PODD (May 22, 2026). Written by software, not financial advice. How we make alerts